Özlem HALİLOĞLU, Özge Polat KORKMAZ, Serdar ŞAHİN, Emre DURCAN, Merve KORKMAZ, Zeynep Oşar SİVA

Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience

Aim: Insulin degludec/aspart (IDegAsp) co-formulation therapy is a novel drug in Turkey and the aim of this study was toretrospectively evaluate the effects of IDegAsp therapy on glycemic control and hypoglycemia in a single tertiary center in Turkey.Material and Methods: The medical records of patients with type 2 diabetes mellitus, who were evaluated at diabetes clinic ofCerrahpaşa Medical Faculty between January and April 2018 and had started to use IDegAsp, were investigated. The demographiccharacteristics of the patients, anti-diabetic medications they were currently using, causes of treatment change, the IDegAsp doses,fasting blood glucose (FBG), HbA1c and hypoglycemic episodes at treatment onset, the third and sixth months of therapy wereevaluated.Results: Sixty-six patients (F/M:34/32; mean age:57.8±11,6years) were evaluated. Uncontrolled hyperglycemia (80.3%) and frequenthypoglycemic attacks (19,7%) were the causes of treatment change. IDegAsp was started as a single dose in 53% and doubledose in 47% of patients. Sixty-two patients (93.9%) were using insulin and the number of injections were signifiantly reduced withIDegAsp (p

PDF

___

1. Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulintreated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014;37:2084-90.
2. American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:90-102.
3. Kumar S, Jang HC, Demirag NG, et al. Effiacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabet Med 2017;34:180-8.
4. Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naive type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence 2015;9:1225-31.
5. Ligthelm RJ, Gylvin T, DeLuzio T, et al . A comparison of twice-daily biphasic insulin aspart 70/30 and oncedaily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract 2011;17:41-50.
6. Haahr H, Fita EG, Heise T. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet 2017;56:339-54.
7. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.Curr Med Res Opin 2011;27:13-20.
8. Haluzik M, Fulcher G, Pieber TR, et al. The coformulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confimed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab 2018;20:1585-92.
9. American Diabetes A. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:55-64.
10. Kaneko S, Chow F, Choi DS, et al. Insulin degludec/ insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26- week, randomised, treat-to-target trial. Diabetes Res Clin Pract 2015;107:139-47.
11. Onishi Y, Ono Y, Rabol R, et al. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 2013;15:826-32.
12. Franek E, Haluzik M, Canecki Varzic S, et al. Twicedaily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes. Diabet Med 2016;33:497-505.
13. Rodbard HW, Cariou B, Pieber TR, et al. Treatment intensifiation with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab 2016;18:274-80.
14. Kalra S, Baruah MP. Insulin degludec aspart: Oneyear real world experience. Indian J Endocrinol Metab 2016;20:369-71.